Hello. My best friend who has recurrent ovarian cancer was recently diagnosed with high risk MDS with complex chromosome abnormality. Although early, her numbers seem to really be improving with Vidaza, but she’s having major injection site issues. Her doctors are going to switch her from injections to using the port that she already has from her ovarian cancer treatment. My question is whether the change from administering the Vidaza via injection versus administering it through her port could in any way impact the effectiveness of the treatment. The doctors say it won’t, and I haven’t been able to find anything that says otherwise. Thank you in advance for any information you may have regarding the issue.